



Innovative biomarkers. Smarter healthcare.

Overview	<p>Astute Medical, Inc. is committed to improving patient outcomes through the identification and validation of unique, new biomarkers. The Company utilizes a proprietary platform to develop and commercialize novel biomarker-based immunoassay tests intended to help clinicians more rapidly assess high-risk medical problems and diseases.</p> <p>Astute Medical's first product, the NEPHROCHECK™ Test, is intended to aid in the risk assessment of patients at risk of acute kidney injury, a complex and highly prevalent condition associated with high mortality rates in critically ill patients. The NEPHROCHECK™ Test is not available for sale in the United States.</p>
History	<p>San Diego-based Astute Medical was founded in 2007. Founders Christopher Hibberd and Paul McPherson previously served on the management team of Biosite Incorporated, playing key roles in the development and commercialization of market-leading immunoassay products.</p>
Customers	<p>Astute Medical's intended customer base includes hospitals worldwide. Because the Company's tests are aimed at acute conditions, physicians caring for critically ill patients are expected to be key beneficiaries of the information provided.</p>
Technology	<p>Astute Medical brings together experts in biomarker research, immunoassay development, engineering, and clinical research to develop and validate tests with excellent assay precision, reproducibility and accuracy.</p> <p>Astute Medical's proprietary method of rigorous biochemical examination is designed to elicit the most meaningful biomarker tools for diseases.</p> <ul style="list-style-type: none">• To identify clinical opportunities, the Company conducts a thorough examination of underserved diseases. This stringent process yields a detailed understanding of key clinical variables including epidemiology, patient care outcomes and economic ramifications for healthcare institutions.• To analyze and identify the most promising biomarker candidates, researchers conduct pilot studies. Then computational analysis is utilized to optimize selection of individual biomarkers or biomarker panels.• Finally, rigorous clinical studies are performed to confirm and extend the pilot results. <p>Commercialized tests are launched on a reliable, easy-to-use platform called the ASTUTE140™ Meter. The ASTUTE140™ Meter is not available for sale in the United States.</p>
Applications	<p>Astute Medical is currently researching potential products for several acute conditions, where existing deficiencies in diagnosis contribute to poor outcomes and/or high cost of care. These include: kidney injury, abdominal pain, acute coronary syndromes, cerebrovascular injury and sepsis.</p> <p>The Company's comprehensive biomarker identification and validation capabilities can identify novel biomarkers leading to the development of new tests to improve healthcare. It is believed that earlier and/or more accurate diagnosis of critical diseases could potentially improve outcomes and reduce the cost of care.</p>
Patents	<p>The intellectual property generated through Astute Medical's endeavors is captured in patent filings.</p>
Financials	<p>Astute Medical is a privately held company. Key investors include De Novo Ventures, Delphi Ventures, Domain Associates, Johnson & Johnson Development Corp., Kaiser Permanente Ventures and MPM Capital.</p>



Innovative biomarkers. Smarter healthcare.

Management

Christopher Hibberd, President & Chief Executive Officer
Paul McPherson, Ph.D., Chief Scientific Officer
W. Todd Myers, Chief Financial Officer
Karin Hughes, Ph.D., Vice President, Clinical & Regulatory Strategy
Eric Perreault, Vice President, Global Marketing and Sales
Philippe Bornibus, Head of Europe

Headquarters

3550 General Atomics Ct.
MS 02/641
San Diego, CA 92121, USA

Website

www.astutemedical.com

Media Contacts

Nadine Padilla
LawPadilla Communications
(619) 507-9306
npadilla@lawpadilla.com